Tissue engineering as a field is rapidly developing in order to provide new scaffolds, tissues and organs or devices to replace or supplement function. One key limitation within tissue engineering is the need for rapid perfusion and microvascularization of implanted tissues. Many investigators are currently focused on the rational design of angiogenic tissue engineering scaffolds which can induce the formation of a microvascular host response. This contribution is critical to the field because recently developed tissue engineering products for use in humans lack microvascularization. These successfully engineered thin tissue components include cartilage, bladder and cornea. The lack of microvascularization limits the types of tissue replacements that can be engineered.
Many disease processes in the United States involve the destruction or damage of organs and tissues. The cause of destruction of these tissues can originate from ischemic insult triggered by cardiovascular disease, infection, auto-immune attack, cancerous invasion, genetic conditions or toxic exposure. Hundreds of conditions can contribute to the destruction of host organs and ultimately necessitate either assistance of organ function or complete organ transplantation in the host. The most common diseases requiring organ transplant include Polycystic Kidney Disease, Diabetes Mellitus, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, Hypertension, Coronary Heart Disease, Cardiomyopathy, Short Gut Syndrome, Cirrhosis and Hepatitis. Tissue Engineering: Daniel J. Gould
Last date updated on March, 2021